Academic History
Ashutosh Wechalekar, MBBS, MD, FRCP, FRCPath, DM, is a Professor of Medicine and Hematology at University College London (UCL), London, UK and a Consultant Hematologist specializing in plasma cell disorders with a focus on monoclonal gammopathy of undetermined significance (MGUS), multiple myeloma, monoclonal protein related disorders (MGRS), and all types of amyloidosis.
Prof. Wechalekar obtained his medical degree from the University of Southampton, Southampton, UK, followed by a Fellowship at the Royal College of Physicians, London, UK. He is part of the largest UK myeloma service and is the Director of the laboratory at the National Amyloidosis Centre, as well as the AL amyloidosis treatment program.
Prof. Wechalekar is active in clinical research, where he is spearheading the development of a trials network for AL amyloidosis across the UK. As Principal Investigator/Chief Investigator, he leads several myeloma clinical trials and has an extensive publication record, contributing to both national and international literature in these fields.
Speaking on novel immunotherapeutic agents and clinical trials for the management of amyloidosis
Prof. Wechalekar delivers insights on innovative strategies and clinical trial data for managing amyloidosis, with a particular emphasis on novel immunotherapeutic approaches. His work centers on clinical trials that explore both monotherapy and combination therapies.
